Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)

2019-06-16 02:23:51 | BioPortfolio

Published on BioPortfolio: 2019-06-16T02:23:51-0400

Clinical Trials [2701 Associated Clinical Trials listed on BioPortfolio]

The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders

This is a single center comparative between-group study and correlational analyses to establish biomarkers of dysmyelination and cognitive impairment in Psychotic Spectrum Disorders using ...

Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum

This protocol describes an attempt to capture the development phase of a mobile support for individuals with schizophrenia. The intent is to describe and account for a rigorous development...

Multi-dimensional Investigations of Negative Emotions and Drug-resistant Auditory Verbal Hallucinations in Psychosis

Auditory verbal hallucinations (AVH) are commonly reported as source of distress, disability and mortality in schizophrenia. Despite proven efficacy of antipsychotics, many patients still ...

Quetiapine in the Treatment of Psychotic Depression - a Pilot Study

Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, prel...

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism

The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders. - 1: Relative to placebo...

PubMed Articles [9010 Associated PubMed Articles listed on BioPortfolio]

Distinguishing prodromal stage of bipolar disorder and early onset schizophrenia spectrum disorders during adolescence.

Prodromal symptoms of bipolar disorder (BD) and early onset schizophrenia spectrum disorder (EOSSD) overlap. To date, there has been no study directly comparing the prodromal stage of both disorders. ...

Schizophrenia, Not a Psychotic Disorder: Bleuler Revisited.

Current diagnostic criteria delineate schizophrenia as a discrete entity essentially defined by positive symptoms. However, the role of positive symptoms in psychiatry is being questioned. There is co...

Specialized Consultation for Suspected Recent-onset Schizophrenia: Diagnostic Clarity and the Distorting Impact of Anxiety and Reported Auditory Hallucinations.

Early detection of psychotic disorders is now recognized as vital in reducing dysfunction, morbidity, and mortality. However, making the diagnosis of a psychotic disorder, especially earlier in the co...

Obesity in Adolescents with Psychiatric Disorders.

This narrative review synthesized recent research related to obesity in adolescents with psychiatric disorders, with a focus on epidemiology, mechanisms, and weight management approaches. The paper re...

Gender dysphoria symptoms in schizophrenia.

Gender dysphoria in individuals with schizophrenia may result from the delusionally changed gender identity or appear regardless of psychotic process. Distinguishing between these situations is not on...

Medical and Biotech [MESH] Definitions

Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning. Individuals have one o more of the following symptoms: delusions, hallucinations, and disorganized speech. (from DSM-5)

Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning.

These disorders are related to both SCHIZOPHRENIA SPECTRUM AND RELATED DISORDERS and DEPRESSIVE DISORDERS in terms of symptomatology, family history, and genetics. (DSM-V) .

A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)

One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.

More From BioPortfolio on "Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)"

Quick Search


Searches Linking to this Trial